Climb Bio, Inc. Common Stock (CLYM) is a publicly traded Healthcare sector company. As of May 21, 2026, CLYM trades at $10.31 with a market cap of $565.73M and a P/E ratio of -11.69. CLYM moved +9.33% today. Year to date, CLYM is +197.18%; over the trailing twelve months it is +748.39%. Its 52-week range spans $1.05 to $12.48. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces CLYM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Climb Bio to present budoprutug Phase 1b/2a 250mg data at EHA June 2026: Climb Bio will showcase safety, B-cell depletion, and initial platelet data from its 250mg budoprutug cohort at the June 13 EHA 2026 Congress following 24 weeks of treatment. The presentation covers Phase 1b/2a results in previously treated primary immune thrombocytopenia patients, informing budoprutug’s clinical profile.
| Metric | Value |
|---|---|
| Price | $10.31 |
| Market Cap | $565.73M |
| P/E Ratio | -11.69 |
| EPS | $-0.88 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.48 |
| 52-Week Low | $1.05 |
| Volume | 59 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.85M |
| Gross Margin | 0.00% |
13 analysts cover CLYM: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.